1. Cuckle HS, van Lith JMM. Appropriate biochemi­cal parameters in first trimester screening for Down’s syn­drome. Prenat Diagn 1999; 19(6): 505-12.

2. Cuckle HS. Improved parameters for risk estimation in Down’s syndrome screening. Prenat Diagn 1995; 15(11): 1057-1065.

3. Wallace EM, Swanston IA, McNeilly AS, Ashby JP, Blundell G, Calder AA, Groome NP. Second trimester screening for Down’s syndrome using maternal serum dimeric inhibin A. Clin Endocrin 1996; 44(1): 17-21.

4. Aitken DA, Wallace EM, Crossley JA, Swanston IA, van Pareren Y, van Maarle M, Groome NP, Macri JM, Connor JM. Dimeric inhibin A as a marker for Down's syndrome and trisomy 18 pregnancies at 7-18 weeks ges­tation. N Engl J Med 1996; 334(19): 1231-1236.

5. Wald NJ, Densem JW, George L, Muttukrishna S, Knight PG. Prenatal screening for Down’s syndrome using Inhibin-A as a serum marker. Prenat Diagn 1996; 16(2): 143-153.

6. Lambert-Messerlain GM, Canick JA, Palomaki GE, Schneyer AL. Second trimester levels of maternal serum inhibin A, total inhibin, inhibin precursor, and activin in Down’s syndrome pregnancy. J Med Screen 1996; 3(2): 58-62.

7. Cuckle HS, Holding S, Jones R, Groome NP, Wallace EM. Combining inhibin A with existing second-trimester markers in maternal serum screening for Down's syndrome. Prenat Diagn 1996; 16(12): 1095-1100.

8. Spencer K, Wallace EM, Ritoe S. Second trimester dimeric inhibin A in Down’s syndrome screening. Prenat Diagn 1996; 16(12): 1101-1110.

9. Wenstrom KD, Owen J, Chu DC, Boots L. -feto­protein, free -human chorionic gonadotropin, and di­meric inhibin A produce the best results in a three analyte, multiple marker screening test for fetal Down’s syndrome. Am J Obstet Gynecol 1997; 177(5): 987-981.

10. Renier MA, Vereecken A, van Herck E, Straet­mans D, Ramaeckers P, Buytaert P. Second trimester maternal dimeric inhibin-A in the multiple-marker screen­ing test for Down’s syndrome. Hum Reprod 1998; 13(3): 744-748.

11. D’Antona DF, Wallace EM, Shearing C, Ashby JP, Groome NP. Inhibin A and pro-_C inhibin in Down syndrome and normal pregnancies. Prenat Diagn 1998; 18(11): 1122-1126.

12. Haddow JE, Palomaki GE, Knight GJ, Foster DL, Neveux LM. Second trimester screening for Down’s syn­drome using maternal serum dimeric inhibin A. J Med Screen 1998; 5(3): 115-119.

13. Lam YH, Tang MHY. Second-trimester maternal serum inhibin-A screening for fetal Down’s syndrome in Asian women. Prenat Diagn 1999; 19(5): 463-467.

14. Yoshida K, Kuwabara Y, Tanaka T, Onda T, Kudo R, Yamamoto H, Sato A, Yanagida K, Okai T, Sakai M, Takai Y, Uemura H, Hoshi K, Fukada Y, Aono T, Maeda K, Ogita S, Ishiko O, Murata Y, Kanzaki T, Myrick F, Grier RE. Dimeric inhibin A as a fourth marker for Down’s syndrome maternal serum screening in native Japanese women. J Obstet Gynaecol Res 2000; 26(3): 171-174.

15. Debieve F, Bouckaert A, Hubinont C, Thomas K. Multiple screening for fetal Down's syndrome with the classic triple test, dimeric inhibin A and ultrasound. Gyne­col Obstet Invest 2000; 49(4): 221-226.

16. Wald NJ, Rodeck C, Hackshaw AK, Walters J, Chitty L, Mackinson AM. First and second trimester ante­natal screening for Down’s syndrome: the results of the Serum, Urine and Ultrasound Screening Study (SURUSS). Health Technol Assess 2003; 7(11): 1-88.

17. Campogrande M, Viora E, Errante G, Bastonero S, Sciarrone A, Grassi Pirrone P, Perona M, Mancini G, Dall'Amico D, Pavanello E, Guaraldo V. Correlations between first and second trimester markers for Down’s syndrome screening. J Med Screen 2001; 8(3): 163-164.

18. Maymon R, Bergman M, Segal S, Dreazen E, Weinraub Z, Herman A. Sequential first and second tri­mester screening tests: correlation of the markers’ levels in normal versus Down syndrome affected pregnancies. Prenat Diagn 2001; 21(13): 1175-1177.

19. Spencer K, Liao AW, Ong CY, Geerts L, Nico­laides KH. Maternal serum levels of dimeric inhibin A in pregnancies affected by trisomy 21 in the first trimester. Prenat Diagn 2001; 21(6): 441-444.

20. Cuckle HS, Sehmi IK, Jones RG. Correlation between maternal serum PAPP-A and inhibin. Prenat Diagn 2002; 22(2): 161-162.

21. Scott F, Boogert A, Sinosich M, Anderson J. Es­tablishment and application of a normal range for nuchal translucency across the first trimester. Prenat Diagn 1996; 16(7): 629-634.

22. Biagiotti R, Periti E, Brizzi L, Vanzi E, Cariati E. Comparison between two methods of standardization for gestational age differences in fetal nuchal translucency measurement in first-trimester screening for trisomy 21. Ultrasound Obstet Gynecol 1997; 9(4): 248-252.

23. Nicolaides KH, Snijders RJ, Cuckle HS. Correct estimation of parameters for ultrasound nuchal translu­cency screening. Prenat Diagn 1998; 18(5): 519-523.

24. de Graaf IM, Prjkrt E, Bilardo CM, Leschot NJ, Cuckle HS, van Lith JMM. Early pregnancy screening for fetal aneuploidy with serum markers and nuchal translu­cency. Prenat Diagn 1999; 19(5): 458-462.

25. Spencer K, Spencer CE, Power M, Moakes A, Nicolaides KH. One stop clinic for assessment of risk for fetal anomalies: a report of the first year of prospective screening for chromosomal anomalies in the first trimester. Br J Obstet Gynaecol 2000; 107(10): 1271-1275.

26. Krantz DA, Hallahan TW, Orlando F, Buchanan P, Larsen JW, Macri JN. First-trimester Down syndrome screening using dried blood biochemistry and nuchal translucency. Obstet Gynecol 2000; 96(2): 207-213.

27. Zoppi MA, Ibba RM, Floris M, Monni G. Fetal nuchal translucency screening in 12495 pregnancies in Sardinia. Ultrasound Obstet Gynecol 2001; 18(6): 649-651.

28. Crossley JA, Aitken DA, Cameron AD, McBride E, Connor JM. Combined ultrasound and biochemical screening for Down’s syndrome in the first trimester: a Scottish multicentre study. Br J Obstet Gynecol 2002; 109(6): 667-676.

29. Lam YH, Lee CP, Sin SY, Tang R, Wong HS, Wong SF, Fong DY, Tang MH, Woo HH. Comparison and integration of first trimester fetal nuchal translucency and second trimester maternal serum screening for fetal Down syndrome. Prenat Diagn 2002; 22(8): 730-735.

30. Herman A, Dreazen E, Herman AM, Batukan CE, Holzgreve W, Tercanli S. Bedside estimation of Down syndrome risk during first-trimester ultrasound screening. Ultrasound Obstet Gynecol 2002; 20(5): 468-475.

31. Snijders RJM, Noble P, Sebire N, Souka A, Nico­laides KH. UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translu­cency thickness at 10-14 weeks of gestation. The Lancet 1998; 352(9125): 343-346.

32. Locatelli A, Piccoli MG, Vergani P, Mariani E, Ghidini A, Mariani S, Pezzullo JC. Critical appraisal of the use of nuchal fold thickness measurements for the prediction of Down syndrome. Am J Obstet Gynecol 2000; 182(1, pt 1): 192-197.

33. Bahado-Singh RO, Oz U, Hsu CD, Deren O, Copel JA, Mahoney MJ. Ratio of nuchal thickness to humerus length for Down syndrome detection. Am J Obstet Gynecol 2001; 184(6): 1284-1288.

34. Souter VL, Nyberg DA, El-Bastawissi A, Zebel­man A, Luthhardt F, Luthy DA. Correlation of ultrasound findings and biochemical markers in the second trimester of pregnancy in fetuses with trisomy 21. Prenat Diagn 2002; 22(3): 175-182.

35. Benn PA, Kaminsky LM, Ying J, Borgida AF, Egan JF. Combined second-trimester biochemical and ultrasound screening for Down syndrome. Obstet Gynecol 2002; 100(6): 1168-1176.

36. Spencer K, Crossley JA, Aitken DA, Nix AB, Dunstan FD, Williams K. Temporal changes in maternal serum biochemical markers of trisomy 21 across the first and second trimester of pregnancy. Ann Clin Biochem 2002; 39(Pt 6): 567-76.

37. Royston P, Thompson SG. Model-based screening by risk with application to Down’s syndrome. Stats in Med 1992; 11(2): 257-268.

38. Cuckle HS, Wald NJ, Thompson SG. Estimating a woman’s risk of having a pregnancy associated with Down’s syndrome using her age and serum a-fetoprotein level. Br J Obstet Gynaecol 1987; 94(5): 387-402.